DiaMedica's Q4 2024 Call: Key Contradictions on Enrollment Rates, Site Activations, and Analysis Plans

These are the key contradictions discussed in DiaMedica Therapeutics' latest 2024Q4 earnings call, specifically including: Enrollment Rate Expectations, Site Activation Timeline, and Statistical Analysis Plan:



Preeclampsia Clinical Program Progress:
- DiaMedica Therapeutics has obtained ethics approval and begun dosing preeclamptic mothers, marking the first study of DM199 in a pregnancy-related condition.
- The rapid progress in the preeclampsia program is attributed to strong collaborations with leading KOLs and trialists.

Stroke Program Site Activation and Enrollment:
- As of March 18, 2025, DiaMedica has activated 30 clinical sites for the ReMEDy2 trial.
- The increase in enrollment is driven by protocol amendments allowing for broader patient inclusion and enhanced communication and support for study sites.

Financial Performance and Cash Runway:
- As of December 31, 2024, DiaMedica reported a total combined cash and investments of $44.1 million, providing a runway into Q3 of 2026.
- The decrease in cash and investments was primarily due to operational expenses, partially offset by net proceeds from a private placement in June 2024.

Scientific and Regulatory Updates:
- A paper on the mechanism of action of DM199 was published in the February 2025 issue of Stroke, providing insights into its potential benefits for acute ischemic stroke (AIS) patients.
- A safety review by the independent Data Safety Monitoring Board (DSMB) in January 2025 did not identify any significant safety concerns, allowing the ReMEDy2 trial to continue without modification.